233 related articles for article (PubMed ID: 36928921)
21. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
Tang Q; Li S; Huang G; Liu H
Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259
[TBL] [Abstract][Full Text] [Related]
22. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
Sotelo M; Alonso-Gordoa T; Gajate P; Gallardo E; Morales-Barrera R; Pérez-Gracia JL; Puente J; Sánchez P; Castellano D; Durán I
Clin Transl Oncol; 2021 Apr; 23(4):882-891. PubMed ID: 32897497
[TBL] [Abstract][Full Text] [Related]
23. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
24. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.
Erlmeier F; Klümper N; Landgraf L; Strissel PL; Strick R; Sikic D; Taubert H; Wach S; Geppert CI; Bahlinger V; Breyer J; Ritter M; Bolenz C; Roghmann F; Erben P; Schwamborn K; Wirtz RM; Horn T; Wullich B; Hölzel M; Hartmann A; Gschwend JE; Weichert W; Eckstein M
Eur Urol; 2023 Feb; 83(2):133-142. PubMed ID: 36372626
[TBL] [Abstract][Full Text] [Related]
25. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
Merseburger AS; Castellano D; Powles T; Loriot Y; Retz M; Voortman J; Huddart RA; Gedye C; Van Der Heijden MS; Gurney H; Ong M; de Ducla S; Pavlova J; Fear S; Sternberg CN
J Urol; 2021 Aug; 206(2):240-251. PubMed ID: 33835866
[TBL] [Abstract][Full Text] [Related]
27. A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma.
Economopoulou P; Kotsantis I; Bamias A
Expert Opin Drug Saf; 2020 Aug; 19(8):955-960. PubMed ID: 32657630
[TBL] [Abstract][Full Text] [Related]
28. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Powles T; O'Donnell PH; Massard C; Arkenau HT; Friedlander TW; Hoimes CJ; Lee JL; Ong M; Sridhar SS; Vogelzang NJ; Fishman MN; Zhang J; Srinivas S; Parikh J; Antal J; Jin X; Gupta AK; Ben Y; Hahn NM
JAMA Oncol; 2017 Sep; 3(9):e172411. PubMed ID: 28817753
[TBL] [Abstract][Full Text] [Related]
30. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
31. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
van der Heijden MS; Loriot Y; Durán I; Ravaud A; Retz M; Vogelzang NJ; Nelson B; Wang J; Shen X; Powles T
Eur Urol; 2021 Jul; 80(1):7-11. PubMed ID: 33902955
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
[TBL] [Abstract][Full Text] [Related]
33. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Niglio SA; Jia R; Ji J; Ruder S; Patel VG; Martini A; Sfakianos JP; Marqueen KE; Waingankar N; Mehrazin R; Wiklund P; Oh WK; Mazumdar M; Ferket BS; Galsky MD
Eur Urol; 2019 Dec; 76(6):782-789. PubMed ID: 31200951
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
[TBL] [Abstract][Full Text] [Related]
35. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
36. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
37. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
38. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.
Burgess EF; Livasy C; Hartman A; Robinson MM; Symanowski J; Naso C; Doherty S; Guerrieri R; Riggs S; Grigg CM; Clark PE; Raghavan D
Urol Oncol; 2019 May; 37(5):299.e19-299.e25. PubMed ID: 30660491
[TBL] [Abstract][Full Text] [Related]
39. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.
Sharma P; Sohn J; Shin SJ; Oh DY; Keam B; Lee HJ; Gizzi M; Kalinka E; de Vos FYFL; Ruscica D; Ferro S; Xiao F; Baverel P; Chen CC; Asubonteng K; Morsli N; Dirix L
Clin Cancer Res; 2020 Jan; 26(1):61-70. PubMed ID: 31801732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
